AstraZeneca PLC (AZN)
| Market Cap | 231.80B |
| Revenue (ttm) | 54.07B |
| Net Income (ttm) | 7.04B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.50 |
| PE Ratio | 16.43 |
| Forward PE | 16.60 |
| Dividend | $1.54 (2.08%) |
| Ex-Dividend Date | Feb 21, 2025 |
| Volume | 7,884,520 |
| Open | 75.57 |
| Previous Close | 72.22 |
| Day's Range | 73.89 - 75.70 |
| 52-Week Range | 62.75 - 87.68 |
| Beta | 0.16 |
| Analysts | Strong Buy |
| Price Target | 89.75 (+21.42%) |
| Earnings Date | Apr 29, 2025 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price forecast is $89.75, which is an increase of 21.42% from the latest price.
News
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting. T...
Pharma stocks survive market rout on tariff exemption, but uncertainty continues
Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from reciprocal tariffs, but executives and analysts warned it was premature to c...
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Pharma tariffs the 'number one question' on investors' minds, Barclays says
Emily Field, head of European pharmaceuticals research at Barclays, weighs in on the potential impact of U.S. tariffs on the pharmaceuticals sector.
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardio...
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, S...
AstraZeneca CEO on its $2.5 billion investment in Beijing hub
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in the Chinese capital.
AstraZeneca to Invest $2.5 Billion in China Amid Probes
The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies, at a time when Chinese authorities are probing it.
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.
Watch CNBC's full interview with Pascal Soriot, AstraZeneca CEO
Pascal Soriot, CEO, AstraZeneca discusses the company's $2.5 billion investment in its new China research and development centre.
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands , March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and comm...
British pharma giant AstraZeneca to invest $2.5 billion in new China hub
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China. Outside the Macclesfield factory of AstraZeneca.
AstraZeneca investing $2.5 bln in China as drugmaker seeks to recover from scandals
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including ...
Mindpeak to deploy and evaluate AI-Powered Digital Pathology Risk Assessment Tools for Breast Cancer in collaboration with AstraZeneca
HAMBURG, Germany--(BUSINESS WIRE)--The collaboration aims to assess the transformative potential of AI in digital pathology, with a specific focus on accelerating primary breast cancer diagnosis. Brea...
IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals
CAMBRIDGE, United Kingdom , March 17, 2025 /PRNewswire/ -- IgniteData has announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and Cambridge University Hospitals NHS Foundation Trust (CUH)...
AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy'
UK pharma group acquires Belgium's EsoBiotec as it announces EU has approved Imfinzi lung cancer drug
AstraZeneca Buys EsoBiotec for Up to $1 Billion
The deal includes the Belgian biotech's vivo cell-therapy platform, which modifies immune cells within the patient's body, potentially increasing access to treatment and reducing costs.
AstraZeneca to buy Esobiotec for upto $1 billion
Drugmaker AstraZeneca on Monday said it will buy biotechnology firm Esobiotec for upto $1 billion.
EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
Acquisition includes EsoBiotec's world-leading in vivo delivery platform with potential to transform cell therapy Acquisition includes EsoBiotec's world-leading in vivo delivery platform with potentia...
Drugmakers agree to participate in second round of price negotiations
All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of price talks have agreed to participate in the negotiation process, a federal h...
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Erin Andrews have teamed up as part of a national public health campaign to educate and empower people to Get Body Checked Against Cancer. Erin is a ...
6 Ideal Buys From 14 'Safer' March Dividends On Bloomberg 2025 Watch List Of 50
Bloomberg Intelligence analysts identified 50 stocks for 2025, focusing on catalysts like new leadership, acquisitions, and AI advancements, with 35 paying dividends. 14 of these dividend-paying stock...
AstraZeneca: A Big Pharma Blue Chip To Buy Now
AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. The company is well-positioned for growth over the next few years. AstraZeneca's net d...
2025 Endothelin Receptor Antagonist Pipeline Insights for 10+ Companies and 15+ Pipeline Drugs, Including Zibotentan (AstraZeneca), SC0062 (Biocity Biopharmaceutics), and GMA301 (Gmax Biopharm)
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Endothelin Receptor Antagonist - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in HER2+ Metastatic Gastric Cancer.